Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL12480286

Nc1cccc(OC(F)(F)F)c1F.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MPL P40238 1/20 0.43
SCN9A Q15858 2/20 0.40
FFAR1 O14842 1/20 0.39
GAA P10253 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
EPHX2 P34913 1/20 0.36
KCNK3 O14649 3/20 0.35
KCNK9 Q9NPC2 3/20 0.35
ATR Q13535 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480337 0.88 MPL (0.51) MPLSCN9AKDM4EMAPTCRHBP
Hydrochloric Acid SCHEMBL12481297 0.86 MPL (0.50) MPLSCN9AGAAKDM4EMAPT
Trifluoroacetic Acid SCHEMBL12480281 0.81 SCN9A (0.44) MPLSCN9AGAARXRARXRB
Trifluoroacetic Acid SCHEMBL3596920 0.78 CES1 (0.44) L3MBTL1
SCHEMBL16093747 0.75 RXRA (0.44) MPLGAARXRARXRBRXRG
Trifluoroacetic Acid SCHEMBL3783854 0.75 MMP2 (0.52) GAAKDM4EMAPTALDH1A1
SCHEMBL12480740 0.73 SCN9A (0.44) MPLSCN9AGAASCN10AKCNK3
SCHEMBL30881819 0.73 SCN9A (0.44) MPLSCN9AGAASCN10AKCNK3
SCHEMBL29177215 0.73 MPL (0.42) MPLSCN9AGAARXRARXRB
Hydrochloric Acid SCHEMBL12480345 0.72 SCN9A (0.44) MPLSCN9AGAASCN10AKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 MPL 65/4885SCN9A 3437/4885FFAR1 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.